Le Lézard
Classified in: Health
Subject: Conference Calls/ Webcasts

Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference


VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the 2024 RBC Capital Markets Global Healthcare Conference taking place May 14-15, 2024 in New York, NY.

Fireside Chat Presentation Details:
  
Date:Tuesday, May 14, 2024
Time:3:35 pm Eastern Time
Webcast:Register here
Presenters:Ian Mortimer, President and Chief Executive Officer
Sherry Aulin, Chief Financial Officer
  

A live webcast of the company presentation will be available on the "Investors" section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. For more information, please visit www.xenon-pharma.com.

"Xenon" and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
[email protected]

For Media:
Jodi Regts
Xenon Corporate Affairs
(604) 484-3353
[email protected]



These press releases may also interest you

at 03:15
Cresilon Announces International Distribution Agreement for VETIGEL with Covetrus
Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on haemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary haemostatic gel, VETIGEL®, to be sold directly...

at 02:30
New Research by Tea Advisory Panel Reveals That Three Quarters Of Brits Never Drink Tea Before A Workout Despite It Counting Towards Fluid Intake Recommendations
Ahead of International Tea Day - 21st May 2024  - and with summer inspiring more of us to get off the sofa to be active, a 2024 real-world research study1 reviewed by the tea science experts at the Tea Advisory Panel ? www.teaadvisorypanel.com -...

at 02:30
TREEFROG PRESENTS DATA FROM THEIR PARKINSON'S DISEASE CELL THERAPY PROGRAM AT THE 29TH WORLD CONGRESS ON PARKINSON'S DISEASE AND RELATED DISORDERS (IAPRD) IN LISBON
TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies.[1]...

at 02:20
Vicore Announces Positive Final Results from the Phase 2a AIR Trial Demonstrating Buloxibutid Improves Lung Function Over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis
Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis...

at 02:07
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Approval
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval....

at 02:05
PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share
PureTech Health plc ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces the opening of its proposed $100 million tender offer (the "Tender...

More news about Health...


News published on and distributed by: